Medizinische Universität Graz - Research portal
Selected Publication:
Aschauer, M; Pilger, E; Szolar, DH; Flueckiger, F; Hausegger, K; Stark, G; Groell, R; Klein, GE; Schreyer, H.
Extended infusion of rtPA lysis of pulmonary emboli: influence of time after onset of symptoms on outcome.
Cardiovasc Intervent Radiol. 1995; 18(5):288-290
Doi: 10.1007/BF00203677
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Aschauer Manuela
- Co-authors Med Uni Graz
- Klein Guenther
- Pilger Ernst
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- PURPOSE: Evaluate efficacy and safety of short-term thrombolysis with recombinant human-tissue plasminogen activator (rtPA). METHODS: Thrombolysis with rtPA was performed in 29 patients with angiographically documented severe acute pulmonary embolism (Miller score of 20/34 or more). All patients received 100 mg rtPA through peripheral veins within the first 2 hr, followed by a continuous infusion of rtPA (0.05 mg/kg/hr) over a 4-hr period. Concomitant intravenous heparin 1000 U/hr infusion was applicated for the first 6 hr. RESULTS: Using this treatment, 83% of our patients showed clinical improvement objectified by the Miller score, by the clinical stage (Grosser), and by the pulmonary artery mean pressure (PAPm). The treatment regimen was unsuccessful if the clinical history lasted more than 3 days. Complications occurred in 10 patients (34%), and 3 patients (10%) died of acute right heart failure. CONCLUSION: The success of rtPA treatment appears to depend on the interval between onset of symptoms and start of thrombolytic therapy. Otherwise the technique leads to objectifiable improvement within 6 hr with an acceptable bleeding risk.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Drug Administration Schedule -
- Female -
- Humans -
- Infusions, Intravenous -
- Male -
- Middle Aged -
- Prognosis -
- Pulmonary Artery - physiopathology
- Pulmonary Embolism - drug therapy
- Pulmonary Wedge Pressure - drug therapy
- Recombinant Proteins - administration and dosage
- Thrombolytic Therapy - administration and dosage
- Time Factors - administration and dosage
- Tissue Plasminogen Activator - administration and dosage
- Find related publications in this database (Keywords)
- ACUTE PULMONARY EMBOLISM
- RECOMBINANT HUMAN-TISSUE PLASMINOGEN ACTIVATOR (RTPA)
- SHORT-TERM THROMBOLYSIS